[go: up one dir, main page]

PL2076244T3 - Układy wodne do wytwarzania związków farmaceutycznych na bazie lipidów; kompozycje, sposoby, oraz ich zastosowanie - Google Patents

Układy wodne do wytwarzania związków farmaceutycznych na bazie lipidów; kompozycje, sposoby, oraz ich zastosowanie

Info

Publication number
PL2076244T3
PL2076244T3 PL07873522T PL07873522T PL2076244T3 PL 2076244 T3 PL2076244 T3 PL 2076244T3 PL 07873522 T PL07873522 T PL 07873522T PL 07873522 T PL07873522 T PL 07873522T PL 2076244 T3 PL2076244 T3 PL 2076244T3
Authority
PL
Poland
Prior art keywords
lipid
compositions
preparation
methods
aqueous systems
Prior art date
Application number
PL07873522T
Other languages
English (en)
Inventor
Shoukath M. Ali
Moghis U. Ahmad
Ateeq Ahmad
Saifuddin Sheikh
Imran Ahmad
Original Assignee
Jina Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jina Pharmaceuticals Inc. filed Critical Jina Pharmaceuticals Inc.
Publication of PL2076244T3 publication Critical patent/PL2076244T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07873522T 2006-10-10 2007-10-10 Układy wodne do wytwarzania związków farmaceutycznych na bazie lipidów; kompozycje, sposoby, oraz ich zastosowanie PL2076244T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85044606P 2006-10-10 2006-10-10
US95702207P 2007-08-21 2007-08-21

Publications (1)

Publication Number Publication Date
PL2076244T3 true PL2076244T3 (pl) 2017-05-31

Family

ID=39864519

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07873522T PL2076244T3 (pl) 2006-10-10 2007-10-10 Układy wodne do wytwarzania związków farmaceutycznych na bazie lipidów; kompozycje, sposoby, oraz ich zastosowanie

Country Status (10)

Country Link
US (2) US20160310600A1 (pl)
EP (1) EP2076244B1 (pl)
JP (2) JP5917789B2 (pl)
CA (1) CA2666322C (pl)
DK (1) DK2076244T3 (pl)
ES (1) ES2617747T3 (pl)
HU (1) HUE031951T2 (pl)
PL (1) PL2076244T3 (pl)
PT (1) PT2076244T (pl)
WO (1) WO2008127358A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510327A (ja) 2006-11-21 2010-04-02 ジャイナ ファーマシューティカルズ,インコーポレーテッド エンドキシフェンの方法および組成物
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
PL2344198T3 (pl) * 2008-09-27 2021-05-31 Jina Pharmaceuticals Inc. Preparaty farmaceutyczne na bazie lipidów do stosowania miejscowego
CA2765541A1 (en) 2009-06-19 2010-12-23 Sun Pharma Advanced Research Company Ltd. Nanodispersion of a drug and process for its preparation
US8591942B2 (en) * 2009-09-23 2013-11-26 Indu JAVERI Methods for the preparation of liposomes comprising docetaxel
US20170340563A1 (en) * 2009-09-23 2017-11-30 Curirx Inc. Methods for the Preparation of Liposomes Comprising Drugs
MX341918B (es) 2011-01-04 2016-09-07 Archivel Farma Sl Formulación de liposomas adecuada para tratar o prevenir la tuberculosis.
US9682042B2 (en) 2012-01-12 2017-06-20 Archivel Farma, S.L. MTB-C vaccine against asthma
US10220095B2 (en) 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
EP3060202A1 (en) * 2013-10-21 2016-08-31 Enzymotec Ltd. Compositions comprising choline and derivatives thereof, uses thereof and processes for their preparation
ES3003920T3 (en) * 2013-11-08 2025-03-11 Activus Pharma Co Ltd Aqueous suspension preparation comprising nanoparticles of macrolide antibacterial agent
EP3150196A1 (en) * 2015-09-30 2017-04-05 Sun Pharma Advanced Research Company Ltd Process for the preparation of unilamellar liposomal composition
AU2017205337B2 (en) * 2016-01-07 2022-09-08 Tesorx Pharma, Llc Formulations for treating bladder cancer
PT3439668T (pt) * 2016-04-08 2024-08-12 Univ Illinois Restauração da fisiologia da superfície das vias aéreas mediada por pequenas moléculas no epitélio pulmonar da fibrose quística humana
US20170290852A1 (en) * 2016-04-08 2017-10-12 Wisconsin Alumni Research Foundation Micelle formulations of amphotericin b
AU2018225546A1 (en) * 2017-02-21 2019-08-29 Satellos Bioscience Inc. Solid oral formulations of amphotericin B
WO2019055880A2 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. METHOD OF ADMINISTRATION AND TREATMENT
AU2018374593B2 (en) * 2017-11-30 2021-09-09 Shilpa Medicare Limited Composition of docetaxel liposomal injection with high drug loading
EP3603682A1 (en) * 2018-08-03 2020-02-05 Alchilife S.r.l. Tablet with an antimycotic agent, medical device and method for preserving harvested corneas
US11857680B2 (en) * 2018-11-26 2024-01-02 Shilpa Medicare Limited Composition of docetaxel liposomal injection with high drug loading
CA3142510A1 (en) * 2019-06-28 2020-12-30 The Board Of Regents, The University Of Texas System Preparation of preliposomal annamycin lyophilizate
CA3182909A1 (en) * 2020-06-15 2021-12-23 Aruna GORUSUPUDI Retinal bioavailability of synthetic very-long-chain polyunsaturated fatty acids
US20230365619A1 (en) * 2020-10-12 2023-11-16 Durect Corporation Crystalline sodium cholesteryl sulfate
WO2022081479A2 (en) * 2020-10-12 2022-04-21 Durect Corporation Crystalline sodium cholesteryl sulfonate
CN119365218A (zh) 2022-03-21 2025-01-24 伊利诺伊大学评议会 包含脂质包覆的两性霉素b晶体的离子通道假体组合物
WO2025064631A1 (en) * 2023-09-20 2025-03-27 The Board Of Trustees Of The University Of Illinois Use of a dry powder inhaler to treat or prevent pulmonary fungal infections
WO2025068971A1 (en) * 2023-09-27 2025-04-03 Jina Pharmaceuticals Inc. Compositions containing cabazitaxel and lipids for oral administration
CN119326735A (zh) * 2024-12-20 2025-01-21 哈尔滨医科大学 一种秋水仙碱制剂及其在制备治疗器官纤维化疾病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5782311A (en) * 1980-11-11 1982-05-22 Tanabe Seiyaku Co Ltd Production of liposome preparation
JPS5782310A (en) * 1980-11-11 1982-05-22 Tanabe Seiyaku Co Ltd Production of liposome preparation
JPS6058915A (ja) * 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd 薬物含有脂質小胞体製剤
US5084269A (en) * 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
WO1992007552A1 (fr) * 1990-11-06 1992-05-14 Nippon Shinyaku Co., Ltd. Preparation lyophilisee et sa production
DE4207481A1 (de) * 1992-03-10 1993-09-16 Bayer Ag Liposomale wirkstoff-formulierungen und verfahren zu ihrer herstellung
ATE223205T1 (de) * 1994-11-18 2002-09-15 Aphios Corp Verfahren zur herstellung von liposomen, die hydrophobische artzneistoffe enthalten
MXPA03003401A (es) * 2000-10-16 2004-06-30 Neopharm Inc Formulacion liposomica de mitoxantrona.
CZ20031515A3 (cs) * 2000-11-09 2003-09-17 Neopharm, Inc. Komplexy SN-38 s lipidem a způsob jejich použití
EP1531800B1 (en) * 2002-06-11 2011-06-08 Ethypharm Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
WO2005044229A1 (en) * 2003-11-05 2005-05-19 The Australian National University Dispersions and methods of preparing them
EP1809254A2 (en) * 2004-10-28 2007-07-25 Alza Corporation Lyophilized liposome formulations and method

Also Published As

Publication number Publication date
JP2010505965A (ja) 2010-02-25
HUE031951T2 (en) 2017-08-28
EP2076244A2 (en) 2009-07-08
US20160310600A1 (en) 2016-10-27
PT2076244T (pt) 2017-03-09
DK2076244T3 (en) 2017-02-27
US20200345849A1 (en) 2020-11-05
EP2076244A4 (en) 2013-01-09
EP2076244B1 (en) 2016-12-07
WO2008127358A2 (en) 2008-10-23
CA2666322A1 (en) 2008-10-23
WO2008127358A3 (en) 2008-12-24
CA2666322C (en) 2013-04-23
JP2016041704A (ja) 2016-03-31
JP5917789B2 (ja) 2016-05-18
ES2617747T3 (es) 2017-06-19

Similar Documents

Publication Publication Date Title
PT2076244T (pt) Sistemas aquosos para a preparação de compostos farmacêuticos à base de lípidos; composições, métodos e utilizações dos mesmos
AU2007299727A8 (en) Self preserved aqueous pharmaceutical compositions
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
ZA200900347B (en) Preparation of pharmaceutical compositions
IL196280A0 (en) Use of ampk-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them
IL198289A (en) Processed dihydropyrazolones, processes for their preparation, medicinal preparations containing them and their use in the preparation of medicinal preparations
ZA200901702B (en) Self-preserved aqueous pharmaceutical compositions
EP1841761A4 (en) Fumagillol derivatives or processes for the preparation of fumagillol derivatives, and pharmaceutical compositions containing them
ZA200903533B (en) Process for the preparation of rosuvastatin
IL195528A (en) Pyridazine compound, methods of preparation, a pharmaceutical composition containing it, its use and intermediate material
IL197877A (en) Uses of aminomethyl-4-imidazole derivatives for the preparation of medications and medications containing them
IL194961A0 (en) Compounds a-r-x for the manufacture of pharmaceutical preparations
IL213452A0 (en) Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
PT2210872T (pt) Nova forma cristalina iii de agomelatina, processo para a sua preparação e composições farmacêuticas que a contêm
ZA201007610B (en) Processes for the preparation of benzo-fused dioxin derivatives
PT2193795E (pt) Composição farmacêutica aquosa contendo latanoprost
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
PL2231598T3 (pl) Nowe pochodne diazeniodiolanów, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
IL213474A0 (en) Processes for the preparation of cyclopropyl-amide derivatives
ZA200901164B (en) Self preserved aqueous pharmaceutical compositions
HUP0600293A2 (en) Zinc salt of rosuvastatine, process for its preparation and pharmaceutical compositions containing it
IL214028A (en) A cyanopyrimidine or salt compound, a pharmaceutical preparation containing it, its use and an aqueous liquid containing the said pharmaceutical composition
ZA200806399B (en) Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them